Concurrent Use of Mepolizumab and Rituximab for Eosinophilic Granulomatosis With Polyangiitis and Multisystem Involvement

Agura Afiari¹, Andre Gabriel², Meghana R. Gaiki³

1. Internal Medicine, University of Connecticut (UConn) School of Medicine, Hartford, USA 2. Internal Medicine, University of Connecticut (UConn) Health, Farmington, USA 3. Nephrology, Saint Francis Hospital and Medical Center, Hartford, USA

Corresponding author: Agura Afiari, afiari@uchc.edu

Abstract

Eosinophilic granulomatosis with polyangiitis (EGPA), formerly Churg-Strauss, is an anti-neutrophil cytoplasmic antibody (ANCA)-associated autoimmune vasculitis, involving small- and medium-sized arteries, which could involve several organs. This rare syndrome can present with a myriad of symptoms, which may make diagnosis challenging. It has been suggested that there are variants of EGPA, which may respond differently to available modes of treatment. Multiple and different mechanisms may be at play in each case of EGPA. This may influence the decision of clinicians to combine treatment strategies as done in this case. The addition of immunosuppressive agents other than high-dose steroids may mitigate end-organ damage, facilitate faster recovery, and prevent relapse. Rituximab among others has been seen to provide better outcomes, including a lower incidence of relapse. Mepolizumab was approved by the Food and Drug Administration (FDA) in 2017 for the treatment of EGPA. Administered at a higher dose than approved for severe eosinophilic asthma, it has been shown to lengthen remission in EGPA. The optimal dose and duration of therapy with mepolizumab remain unclear. The rarity alone of EGPA creates room for further investigation regarding pathogenesis, outcome over time, and treatment strategies, which may vary depending on how an individual case presents.

This case describes the course of a 55-year-old woman who presented with respiratory symptoms, pauci-immune necrotizing granulomatous nephropathy, and neuropathy secondary to P-ANCA-positive EGPA who was successfully treated with rituximab and mepolizumab, in addition to glucocorticoids.

Categories: Internal Medicine, Allergy/Immunology, Nephrology

Keywords: mepolizumab, egpa, rituximab, glomerulonephritis, vasculitis

Introduction

Eosinophilic granulomatosis with polyangiitis (EGPA), formerly Churg-Strauss, is an anti-neutrophil cytoplasmic antibody (ANCA)-associated autoimmune vasculitis involving small- and medium-sized arteries. It was first described in 1949 in a group of patients with eosinophilia, asthma, fever, and vasculitis, which involved several organs [1]. For this reason, this syndrome can present with a myriad of symptoms that may make diagnosis challenging. The incidence of EGPA in the United States has been estimated at 1.3/100,000 [2]. With this knowledge, there is the concern that EGPA is underdiagnosed and there is limited understanding of its pathophysiology, hence, there is room to optimize current therapy or even discover new treatment strategies. It has been suggested that there are variants of EGPA that may respond differently to available modes of treatment. Immunosuppressive agents, including cyclophosphamide, azathioprine, mycophenolate mofetil, rituximab, and, more recently, mepolizumab, are shown to be effective in different treatment strategies.

The case below describes the course of a 55-year old woman who presented with respiratory symptoms, nephropathy, and, neuropathy secondary to P-ANCA-positive EGPA and was successfully treated with rituximab and mepolizumab, in addition to glucocorticoids.

Case Presentation

A 55-year old female with a past medical history of bilateral knee osteoarthritis, hypertension, and hypothyroidism presented to her primary care provider with joint pain and body aches for some months. She had visited the emergency department a few times for these symptoms and was managed with short courses of low-dose prednisone. outpatient lab work revealed C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) significantly elevated. Other immune markers, including anti-dsDNA, anti-Ro, anti-La, anti-Smith, RNP, RF, CCP, and HLA-B27, were found to be in the normal range. She was diagnosed with polymyalgia rheumatica and prescribed prednisone 15 mg to be taken daily.

Six months later, she returned to the primary care physician's office with vague symptoms of low-grade

Received 06/22/2020
Review began 07/06/2020
Review ended 07/07/2020
Published 07/17/2020

© Copyright 2020

Afiari et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

How to cite this article

Afiari A, Gabriel A, Gaiki M R (July 17, 2020) Concurrent Use of Mepolizumab and Rituximab for Eosinophilic Granulomatosis With Polyangiitis and Multisystem Involvement. Cureus 12(7): e9242. DOI 10.7759/cureus.9242

fevers, dry cough, nasal and sinus congestion, paresthesia and numbness of her feet, malaise, and nausea. She stated that she had tapered down her prednisone unbeknownst to her rheumatologist. She denied nonsteroidal anti-inflammatory drugs (NSAIDs) use, new medications, poor oral intake, diarrhea, vomiting, rash, dysgeusia, and pruritus. She reported taking herbal supplements, including turmeric. She was on pantoprazole for gastroesophageal reflux disease.

Due to acute renal failure, seen in outpatient lab work, she was sent to the hospital for further evaluation. Vitals were stable on room air and her physical exam was unrevealing. Lab work was significant for blood urea nitrogen (BUN)/creatinine (Cr) 41/3.4 (baseline creatinine 0.8 a year prior), white blood cell (WBC) 14.6, eosinophils 3600 (normal 15-500 eos/microL). P-ANCA >1:320. Urine microscopy showed microscopic hematuria with both normal and dysmorphic red blood cells (RBCs). There were no casts and rare WBCs. The renal ultrasound (US) was unrevealing. A chest CT (Figure 1) was obtained that revealed multifocal nodular airspace opacities. She was started on pulse dose steroids. Renal biopsy revealed necrotizing and crescentic glomerulonephritis, (pauci-immune type), necrotizing granulomatous arteritis, and severe eosinophilic and neutrophilic tubulointerstitial infiltrate (Figures 2-4). Electromyography (EMG) showed asymmetric sensorimotor polyneuropathy affecting the lower extremities (L>R) due to chronic axonal and secondary demyelinating (mixed) nerve injury (Figures 5-7). The decision was made to place her on rituximab weekly for four doses and mepolizumab 300 mg monthly, which were started while inpatient. Steroid taper was continued and atovaquone was added for *Pneumocystis jiroveci* pneumonia (PJP) prophylaxis. She has been able to return to work full time. Two months after, her renal function stabilized with creatinine at 1.6 mg/dl, improvement in wheezing and congestion, occasional cough, and persistent left foot paresthesia.

FIGURE 1: Multifocal nodular airspace opacities seen on chest CT

Sub-panel A: axial view showing multifocal opacities (black arrow); Sub-panel B: coronal view showing multifocal nodular opacities (blue arrows)

CT: computed tomography

FIGURE 2: Necrotizing and crescentic glomerulonephritis

FIGURE 3: Necrotizing granulomatous arteritis

FIGURE 4: Necrotizing granulomatous arteritis

FIGURE 5: Motor nerve conduction studies of right and left tibial muscles

Motor Summary Table												
Stim Site	NR	O-P Amp (mV)	Norm O-P Amp	Onset (ms)	Norm Onset (ms)	Neg Area (mVms)	Neg Dur (ms)	Site1	Site2	Dist (cm)	Vel (m/s)	Norm Vel (m/s)
Left Median Motor (Thenar)												
Wrist		5.1	>4	3.9	<4.4	12.39	4.84	Wrist	Thenar	7.0		
Elbow		4.3	>4	9.5		10.95	4.22	Elbow	Wrist	24.0	43	>49
Left Peroneal Motor (Ext Dig Brev)												
Ankle		1.0	>2	5.8	<6.1	2.85	5.47	Ankle	Ext Dig Brev	9.0		
B Fib		0.6	>2	16.2		2.10	6.48	B Fib	Ankle	35.0	34	>41
Poplt		0.6	>2	18.1		1.95	7.42	Poplt	B Fib	7.0	37	>41
Right Peroneal Motor (Ext Dig Brev)												
Ankle		2.1	>2	5.4	<6.1	6.91	5.86	Ankle	Ext Dig Brev	9.0		
B Fib		1.6	>2	13.9		5.18	6.88	B Fib	Ankle	35.0	41	>41
Poplt		1.4	>2	15.7		4.29	6.25	Poplt	B Fib	7.0	39	>41
Left Tibial Motor (Abd Hall Brev)												
Ankle	NR		>3		<6.1			Ankle	Abd Hall Brev	8.0		
Right Tibial Motor (Abd Hall Brev)												
Ankle		2.4	>3	3.9	<6.1	5.70	5.08	Ankle	Abd Hall Brev	8.0		
Knee		0.8	>3	13.9		5.89	11.56	Knee	Ankle	39.0	39	>41

FIGURE 6: Motor nerve conduction studies summary

Electrodiagnostic evidence of an asymmetric sensorimotor polyneuropathy (mild to moderate), primarily affecting the lower extremities (L>R), due to chronic axonal and secondary demyelinating nerve injury

FIGURE 7: Left and right peroneal motor nerve conduction studies

Discussion

Eosinophilic granulomatosis with polyangiitis (EGPA), formerly Churg-Strauss syndrome, is autoimmune

vasculitis involving small- and medium-sized arteries, which could potentially lead to pathology in all organs. The typical presentation is a patient with upper and/or lower respiratory symptoms and further investigation leading to the detection of eosinophilia. As any organ system may be affected, the presentation may vary widely and may also be nonspecific. The above patient reported a history of allergies for years before her presentation. She ultimately presented with upper and lower respiratory symptoms, paresthesia, and numbness of feet confirmed as demyelinating polyneuropathy by electromyography (EMG) and renal failure (biopsy result above). P-ANCA being more common than C-ANCA, the incidence of ANCA-associated vasculitis is rare, with EGPA being the rarest of the three and the others being microscopic polyangiitis and granulomatosis with polyangiitis (Wegener's). These are also to be considered in the evaluation of a patient with the pulmonary-renal syndrome.

Using both the American College of Rheumatology (ACR) [3] and Lanham [4] criteria, the above patient's presentation was diagnostic for EGPA. The presence of extrapulmonary manifestation helps in narrowing the diagnosis, as other eosinophilic lung diseases may present similarly. Among others, acute interstitial nephritis secondary to drugs, infections, as part of autoimmune diseases (for example, immunoglobulin G4 (IgG4)-related kidney disease), and drug rash with eosinophilia and systemic symptoms (DRESS), are to be considered possible diagnoses in renal dysfunction with eosinophilia presentation.

The pathogenesis of EGPA is yet to be fully elucidated. A pauci-immune process is seen in the renal biopsy from the above case. This seems to be predominant in EGPA as opposed to other vasculitides where immune complex deposition has been described. Multiple and different mechanisms may be at play in each case of EGPA. Our patient had recently weaned herself to lower doses of prednisone and was seen to have a high P-ANCA titer of >1:320. These together may have played a role in the pathophysiology, specifically in this case. Comarmond et al. describe a different pattern of presentation in patients with P-ANCA positive vs P-ANCA negative EGPA [5]. A predominance of renal involvement and peripheral neuropathy in ANCA positivity has been demonstrated [6], which is seen in the above case.

We decided it was necessary to add on other immunosuppressive agents other than high-dose steroids because of the degree of multisystem involvement observed. This was to mitigate end-organ damage and facilitate faster recovery and prevention of relapse. Rituximab and mepolizumab were used with glucocorticoids for both induction and maintenance therapy. This may have been of added benefit considering likely multiple players in the pathogenesis of EGPA. The mainstay of treatment is immunosuppression with corticosteroids and other immunomodulators. Such drugs, including cyclophosphamide, mycophenolate mofetil, azathioprine, and rituximab among others, in addition to steroid chronic therapy, have been seen to provide better outcomes including a lower incidence of relapse. Thiel et al. demonstrated rituximab as an effective therapy for induction remission even in EGPA patients who had been refractory to standard therapy, including cyclophosphamide [7]. It may also be more beneficial to ANCA-positive patients [8]. The side-effect profile of each immunosuppressive agent must be considered per patient when determining which is most suitable.

Mepolizumab was approved by FDA in 2017 for the treatment of EGPA. It is a monoclonal antibody that affects the pathway leading to eosinophil maturation and activation via interleukin 5 antagonism. Concurrent use of mepolizumab and rituximab (destruction of CD20+ B lymphocytes) for our patient will target different pathways of the immune system involved in eosinophil activation, which, in theory, can produce a synergistic effect in the treatment of EGPA compared to the use of each agent alone. Mepolizumab has been shown to provide longer periods of remission [9]. For this reason, a randomized control trial by Wechsler et al. used 300 mg of mepolizumab administered subcutaneously every four weeks (compared to 100 mg used in severe eosinophilic asthma), which showed longer remission and lower rates of relapse in patients with EGPA refractory to other modes of therapy [10]. In a case report, 100 mg of mepolizumab was successfully used for maintenance therapy after induction with rituximab in a patient who presented with diffuse alveolar injury in the setting of cyclophosphamide refractory EGPA [11]. This raises the question of what the optimal dose for EGPA is. Also, the optimal duration of therapy with mepolizumab remains unclear, as cases of relapse after discontinuation have been documented. Other studies have described the possible benefit of plasma exchange [12] and renal transplantation [13] in patients with more severe renal dysfunction and ESRD, respectively.

Conclusions

The rarity of EGPA alone creates room for further investigation regarding pathogenesis, outcome over time, and treatment strategies. The possibility of several mechanisms at play in the pathogenesis may mean that different treatment options may be required depending on how each case presents. The presence or absence of P-ANCA, what organ system is involved, the severity of the illness, the age of the patient, may all need to be considered when determining treatment modalities. The observed reduction in mortality rates from earlier suggests that some progress has been made so far. In this case, a biopsy of the kidney early in the disease process provided the benefit of a clearer diagnosis and, hence, better targeted, and early treatment, preventing progression to more severe renal injury.

Additional Information

Disclosures

Human subjects: Consent was obtained by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Strauss L, Churg J, Zak FG: Cutaneous lesions of allergic granulomatosis; a histopathologic study. *J Invest Dermatol.* 1951, 17:349-359. [10.1038/jid.1951.103](https://doi.org/10.1038/jid.1951.103)
2. Berti A, Cornec D, Crowson CS, Specks U, Matteson EL: The epidemiology of antineutrophil cytoplasmic autoantibody-associated vasculitis in Olmsted County, Minnesota: a twenty-year US population-based study. *Arthritis Rheumatol.* 2017, 69:2338-2350. [10.1002/art.40313](https://doi.org/10.1002/art.40313)
3. Masi AT, Hunder GG, Lie JT, et al.: The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). *Arthritis Rheum.* 1990, 33:1094-1100. [10.1002/art.1780330806](https://doi.org/10.1002/art.1780330806)
4. Lanham JG, Elkon KB, Pusey CD, Hughes GR: Systemic vasculitis with asthma and eosinophilia. A clinical approach to the Churg-Strauss syndrome. *Medicine.* 1984, 63:65-81. [10.1097/00005792-198403000-00001](https://doi.org/10.1097/00005792-198403000-00001)
5. Comarmond C, Pagnoux C, Khellaf M, et al.: Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. *Arthritis Rheum.* 2013, 65:270-281. [10.1002/art.37721](https://doi.org/10.1002/art.37721)
6. Sablé-Fourtassou R, Cohen P, Mahr A, et al.: Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome background. *Ann Intern Med.* 2005, 143:632-638. [10.7326/0003-4819-143-9-200511010-00006](https://doi.org/10.7326/0003-4819-143-9-200511010-00006)
7. Thiel J, Hässler F, Salzer U, Voll RE, Venhoff N: Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). *Arthritis Res Ther.* 2013, 15:R133. [10.1186/ar4313](https://doi.org/10.1186/ar4313)
8. Mohammad AJ, Hot A, Arndt F, et al.: Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). *Ann Rheum Dis.* 2016, 75:396-401. [10.1136/annrheumdis-2014-206095](https://doi.org/10.1136/annrheumdis-2014-206095)
9. Faverio P, Bonaiti G, Bini F, Vaghi A, Pesci A: Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy. *Ther Clin Risk Manag.* 2018, 14:2385-2396. [10.2147/TCRM.S159949](https://doi.org/10.2147/TCRM.S159949)
10. Wechsler ME, Akuthota P, Jayne D, et al.: Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. *N Engl J Med.* 2017, 376:1921-1932. [10.1056/NEJMoa1702079](https://doi.org/10.1056/NEJMoa1702079)
11. Shiroshita A, Nakashima K, Motojima S, Aoshima M: Refractory diffuse alveolar hemorrhage caused by eosinophilic granulomatosis with polyangiitis in the absence of elevated biomarkers treated successfully by rituximab and mepolizumab: a case report. *Respir Med Case Rep.* 2019, 26:112-114. [10.1016/j.rmcr.2018.12.010](https://doi.org/10.1016/j.rmcr.2018.12.010)
12. De Luna G, Chauveau D, Anriot J, et al.: Plasma exchanges for the treatment of severe systemic necrotizing vasculitides in clinical daily practice: data from the French Vasculitis Study Group. *J Autoimmun.* 2015, 65:49-55. [10.1016/j.jaut.2015.08.003](https://doi.org/10.1016/j.jaut.2015.08.003)
13. Park ES, Ahn SS, Jung SM, Song JJ, Park YB, Lee SW: Renal outcome of kidney-transplantation in Korean recipients with ANCA-associated vasculitis. *Clin Exp Rheumatol.* 2018, 36:115-120.